Novartis Animal Health and Morphogenesis to develop cancer vaccine

24 March 2010 00:00 in Animal Health Supplier News


Novartis Animal Health is to move ahead with the development of a potentially promising new cancer treatment platform with partner Morphogenesis.

As part of an exclusive worldwide co-development and commercialisation agreement signed late last year, the firms are to create a number of cancer vaccines for dogs, while Novartis will also gain the rights to Morphogenesis' canine and feline cancer cell lines.

The two companies are set to work together closely to bring these products to market, with Morphogenesis due to receive a number of milestone payments based on the developmental and commercial progress of the drugs.

Dr Patricia Lawman, chief executive officer of Morphogenesis, stated that the partnership represents a "new chapter" in the treatment of canine cancer.

She added: "We share the common objective of finding treatments for serious animal diseases where there exist significant unmet needs."

Last week, Novartis Animal Health launched its new sheep drench product Zolvix in the UK, which is designed to help combat harmful parasites.

Other news stories from 24/03/2010

• Siemens launches new bleeding risk assessment test
• Ipsen expands deal with GTx for cancer treatment
• Sanofi-aventis receives EU approval for heart disease treatment
• GlaxoSmithKline commits to vaccine alliance for poorer countries
• Pfizer to provide new vaccine to developing nations
• Haemonetics wins praise for corporate responsibility
• Sempermed launches new nitrile glove range
• Source BioScience records first annual profit in 2009
• Smoking and hair dye 'increase risk of progressive liver disease'
• Ecolab recognised for corporate ethics
• Novartis Animal Health and Morphogenesis to develop cancer vaccine

Related news

• Novartis adds MedAdNews award to growing list of accolades
• Novartis Animal Health closes entries for New Zealand scholarship
• Novartis Animal Health offers seasonal nematodirus warning
• Novartis Animal Health launches new flukicide for cattle and sheep
• Novartis Animal Health and Morphogenesis to develop cancer vaccine

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency

Feedback | News Archive | Browse News | Hotels | Links | Browse Jobs | Legal Notice | Privacy Policy

© Copyright 2013 Zenopa Ltd